Immunotherapy failure in adrenocortical cancer: where next?

Deborah Cosentini; Salvatore Grisanti; Alberto Dalla Volta; Marta Laganà; Chiara Fiorentini; Paola Perotti; Sandra Sigala; Alfredo Berruti

doi:10.1530/EC-18-0398

Endocrine Connections (Nov 2018)

Immunotherapy failure in adrenocortical cancer: where next?

Deborah Cosentini,
Salvatore Grisanti,
Alberto Dalla Volta,
Marta Laganà,
Chiara Fiorentini,
Paola Perotti,
Sandra Sigala,
Alfredo Berruti

Affiliations

Deborah Cosentini: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy
Salvatore Grisanti: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy
Alberto Dalla Volta: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy
Marta Laganà: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy
Chiara Fiorentini: Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
Paola Perotti: Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Italy
Sandra Sigala: Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
Alfredo Berruti: Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy

DOI: https://doi.org/10.1530/EC-18-0398
Journal volume & issue: Vol. 7, no. 12
pp. E5 – E8

Abstract

Read online

Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). This editorial focus on the possible mechanisms of ACC immunoevasion and suggests strategies to overcome the intrinsic immunotherapy resistance of this disease.

Published in Endocrine Connections

ISSN: 2049-3614 (Online)
Publisher: Bioscientifica
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the endocrine glands. Clinical endocrinology
Website: http://www.endocrineconnections.com/

About the journal